| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MRPL35 |
| Uniprot No | Q9NZE8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188 aa |
| 活性数据 | MAASAFAGAVRAASGILRPLNILASSTYRNCVKNASLISALSTGRFSHIQTPVVSSTPRLTTSERNLTCGHTSVILNRMAPVLPSVLKLPVRSLTYFSARKGKRKTVKAVIDRFLRLHCGLWVRRKAGYKKKLWKKTPARKKRLREFVFCNKTQSKLLDKMTTSFWKRRNWYVDDPYQKYHDRTNLKV |
| 分子量 | 47.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MRPL35蛋白的3篇示例参考文献(注：内容为假设性概括，实际文献可能需要通过学术数据库确认)：
1. **"Functional characterization of mitochondrial ribosomal protein L35 in mammalian oxidative phosphorylation"**
- **作者**: Lee, J. et al.
- **摘要**: 研究了MRPL35在线粒体翻译和氧化磷酸化中的作用，发现其缺失导致线粒体核糖体组装缺陷，进而抑制呼吸链复合体的合成和细胞能量代谢。
2. **"Recombinant expression and purification of human MRPL35 for structural analysis"**
- **作者**: Zhang, Y. et al.
- **摘要**: 报道了在大肠杆菌系统中高效表达并纯化重组人MRPL35蛋白的方法，并通过质谱和圆二色光谱验证其结构和稳定性，为功能研究提供材料基础。
3. **"MRPL35 mutations impair mitochondrial translation and cause early-onset neurological disorders"**
- **作者**: Smith, R. et al.
- **摘要**: 鉴定了MRPL35的致病性突变，发现其导致线粒体翻译功能紊乱，与婴儿期脑病和肌肉功能障碍相关，揭示了该蛋白在神经发育中的关键作用。
4. **"MRPL35 regulates apoptosis through interaction with Bcl-2 family proteins"**
- **作者**: Chen, L. et al.
- **摘要**: 揭示MRPL35通过调控Bax/Bcl-2比例影响线粒体膜通透性，从而参与细胞凋亡通路，提示其在癌症治疗中的潜在靶点价值。
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“MRPL35”或“mitochondrial ribosomal protein L35”获取最新研究。
Recombinant human MRPL35 (Mitochondrial Ribosomal Protein L35) is a nuclear-encoded protein component of the mitochondrial ribosome's large subunit (39S). As part of the mitoribosome, MRPL35 plays a critical role in mitochondrial protein synthesis, specifically in translating the 13 essential polypeptides encoded by mitochondrial DNA (mtDNA) for oxidative phosphorylation (OXPHOS) complexes. This ~30 kDa protein contains conserved structural domains typical of ribosomal proteins, facilitating interactions with rRNA and coordinating translational fidelity.
Dysregulation of MRPL35 has been linked to mitochondrial dysfunction, which underlies metabolic disorders, neurodegenerative diseases, and certain cancers. Recombinant MRPL35 is typically produced via heterologous expression systems (e.g., E. coli or mammalian cells) with affinity tags for purification. Its recombinant form enables functional studies, including mitochondrial translation assays, structural analyses (e.g., cryo-EM), and investigations into mitoribosome assembly pathways.
Recent studies highlight MRPL35's potential as a biomarker or therapeutic target in conditions like colorectal cancer, where its overexpression correlates with poor prognosis. Researchers also utilize recombinant MRPL35 as an antigen for antibody development or as a reagent to study mitochondrial gene expression regulation. Ongoing work focuses on elucidating its post-translational modifications and tissue-specific roles in mitochondrial homeostasis.
×
